Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 8/20 | 0.98 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.98 |
| ▸ | NPSR1 | Q6W5P4 | 6/20 | 0.98 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.98 |
| ▸ | MEN1 | O00255 | 4/20 | 0.98 |
| ▸ | GAA | P10253 | 2/20 | 0.98 |
| ▸ | IDE | P14735 | 1/20 | 0.98 |
| ▸ | XBP1 | P17861 | 1/20 | 0.98 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.98 |
| ▸ | MAPT | P10636 | 4/20 | 0.69 |
| ▸ | TP53 | P04637 | 3/20 | 0.69 |
| ▸ | F8 | P00451 | 1/20 | 0.69 |
| ▸ | F5 | P12259 | 1/20 | 0.69 |
| ▸ | SLC5A2 | P31639 | 2/20 | 0.68 |
| ▸ | HTT | P42858 | 5/20 | 0.68 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.68 |
| ▸ | TSHR | P16473 | 3/20 | 0.68 |
| ▸ | THRB | P10828 | 1/20 | 0.68 |
| ▸ | MITF | O75030 | 1/20 | 0.68 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17749503 | 0.86 | SMN1; SMN2 (0.74) | LMNAKMT2ANPSR1SMN1; SMN2MEN1 | |
| SCHEMBL17749492 | 0.85 | LMNA (0.73) | LMNAKMT2ANPSR1SMN1; SMN2MEN1 | |
| SCHEMBL2496035 | 0.84 | LMNA (0.89) | LMNAKMT2ANPSR1SMN1; SMN2MEN1 | |
| SCHEMBL2495066 | 0.82 | LMNA (0.98) | LMNAKMT2ANPSR1SMN1; SMN2MEN1 | |
| SCHEMBL2494794 | 0.82 | LMNA (0.98) | LMNAKMT2ANPSR1SMN1; SMN2MEN1 | |
| SCHEMBL17749565 | 0.82 | TP53 (0.71) | LMNAKMT2ANPSR1SMN1; SMN2MEN1 | |
| SCHEMBL17761742 | 0.82 | TP53 (0.71) | LMNAKMT2ANPSR1SMN1; SMN2MEN1 | |
| SCHEMBL17749545 | 0.82 | SMN1; SMN2 (1.00) | LMNAKMT2ANPSR1SMN1; SMN2MEN1 | |
| SCHEMBL17761713 | 0.82 | TP53 (0.71) | LMNAKMT2ANPSR1SMN1; SMN2MEN1 | |
| SCHEMBL2496455 | 0.81 | SLC5A2 (1.00) | LMNAKMT2ANPSR1SMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016077541-A1 | NOVEL ANTI-INFECTIVE COMPOUNDS AND METHODS USING SAME | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2016-05-19 | — | — | WO | claimed |
| EP-2373629-B1 | COMPOUNDS FOR TREATING CANCER | BOEHRINGER INGELHEIM INT (DE) | 2013-04-10 | — | — | EP | claimed |
| US-20110312969-A1 | COMPOUNDS FOR TREATING CANCER | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-12-22 | — | — | US | claimed |
| EP-2373629-A1 | COMPOUNDS FOR TREATING CANCER | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-10-12 | — | — | EP | claimed |
| WO-2010067067-A1 | COMPOUNDS FOR TREATING CANCER | EVOTEC AG (DE) | 2010-06-17 | — | — | WO | claimed |
| WO-2016077541-A1 | NOVEL ANTI-INFECTIVE COMPOUNDS AND METHODS USING SAME | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2016-05-19 | — | — | WO | disclosed |
| WO-2016077541-A1 | NOVEL ANTI-INFECTIVE COMPOUNDS AND METHODS USING SAME | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2016-05-19 | — | — | WO | disclosed |
| US-8759520-B2 | Compounds for treating cancer | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-06-24 | — | — | US | disclosed |
| US-8759520-B2 | Compounds for treating cancer | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-06-24 | — | — | US | disclosed |
| US-8759520-B2 | Compounds for treating cancer | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-06-24 | — | — | US | disclosed |
| EP-2373629-B1 | COMPOUNDS FOR TREATING CANCER | BOEHRINGER INGELHEIM INT (DE) | 2013-04-10 | — | — | EP | disclosed |
| US-20110312969-A1 | COMPOUNDS FOR TREATING CANCER | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-12-22 | — | — | US | disclosed |
| US-20110312969-A1 | COMPOUNDS FOR TREATING CANCER | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-12-22 | — | — | US | disclosed |
| US-20110312969-A1 | COMPOUNDS FOR TREATING CANCER | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110312969-A1 | COMPOUNDS FOR TREATING CANCER | BCL2, BAX, BCL2A1 | LMNA 2691/4885KMT2A 2214/4885NPSR1 2588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.